Category Archives: Biotechnology

Thursday, January 16, 2020

In a coordinated effort, the Food and Drug Administration (FDA), the U.S. Department of Agriculture (USDA), and the Environmental Protection Agency (EPA) launched a Unified Website for Biotechnology Regulation on January 9, 2020. The website serves to streamline information regarding agriculture biotechnology products, which are regulated by FDA, USDA, and EPA. The implementation of the website is in response to the June 2019 Executive Order issued by President Donald Trump on Modernizing the Regulatory Framework for Agricultural Biotechnology Products. The Unified Website for Biotechnology Regulation complements prior joint actions such as the Coordinated Framework for the Regulation of Biotechnology, an Obama administration effort to reform the biotechnology regulatory process by enhancing transparency, predictability, and efficacy. Mintz has previously covered these coordinated efforts here.

Agriculture biotechnology products are products created through genetic engineering of plants, animals, and microbes. Each agency has a role in regulating biotechnology products: USDA has authority to approve all releases of genetically modified organisms (GMOs) to ensure they do not create an environmental hazard; EPA must approve all crops that contain insect-killing genes; and FDA is responsible for evaluating whether GMOs are safe to eat. However, because of the interrelatedness of this area, agency regulatory oversight can be disjointed and unclear. Additionally, the advancement of technology can cause confusion in interpreting the regulatory requirements of each agency. Therefore, a primary goal of the website is to enhance customer service by allowing users to submit questions directly to the three agencies, as well as through providing a Frequently Asked Questions page.

The Unified Website for Biotechnology Regulation does not alter the regulatory process concerning agriculture biotechnology products. Instead, the website acts as an interactive archive containing information about the federal review process, while also enabling users to submit questions to the regulatory agencies with the expectation of a coordinated response. According to the FDA Press Release, "[t]he goals of this website are to provide enhanced customer service to innovators and developers, while ensuring Americans continue to enjoy the safest and most affordable food supply in the world and can learn more about the safe use of biotechnology innovations.

The website launch follows the October 2018 FDA announcement for its Plant and Animal Biotechnology Action Plan, which provides a risk-based regulatory approach to the oversight of plant and animal-derived products of biotechnology, with a focus on safety and effectiveness. One of the action plan's priorities is to coordinate a new biotechnology approach with EPA and USDA to clarify oversight of genome-edited products. According to FDA Commissioner Stephen Hahn, M.D.: This is a time of unprecedented scientific innovation. Agricultural biotechnology promises to bring dynamic new products to the marketplace . . . Our approach balances our internationally respected, science-based review standards with our ongoing risk-based regulatory approaches to ensure the safety of our food supply.

While the Unified Website for Biotechnology Regulation is a step towards meeting the goals set in the June 2019 Executive Order, additional efforts are needed to better coordinate biotechnology product regulation as technology continues to advance.

1994-2020 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. All Rights Reserved.

Continue reading here:
Unified Biotechnology Regulation Website Launched - The National Law Review

Ross Murdoch has been the CEO of Avecho Biotechnology Limited (ASX:AVE) since 2015. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we'll look at a snap shot of the business growth. Third, we'll reflect on the total return to shareholders over three years, as a second measure of business performance. The aim of all this is to consider the appropriateness of CEO pay levels.

Check out our latest analysis for Avecho Biotechnology

Our data indicates that Avecho Biotechnology Limited is worth AU$7.9m, and total annual CEO compensation was reported as AU$404k for the year to December 2018. We think total compensation is more important but we note that the CEO salary is lower, at AU$351k. We examined a group of similar sized companies, with market capitalizations of below AU$289m. The median CEO total compensation in that group is AU$379k.

So Ross Murdoch receives a similar amount to the median CEO pay, amongst the companies we looked at. This doesn't tell us a whole lot on its own, but looking at the performance of the actual business will give us useful context.

You can see a visual representation of the CEO compensation at Avecho Biotechnology, below.

ASX:AVE CEO Compensation, January 14th 2020

On average over the last three years, Avecho Biotechnology Limited has grown earnings per share (EPS) by 65% each year (using a line of best fit). It achieved revenue growth of 310% over the last year.

This shows that the company has improved itself over the last few years. Good news for shareholders. Most shareholders would be pleased to see strong revenue growth combined with EPS growth. This combo suggests a fast growing business. Although we don't have analyst forecasts shareholders might want to examine this detailed historical graph of earnings, revenue and cash flow.

With a three year total loss of 80%, Avecho Biotechnology Limited would certainly have some dissatisfied shareholders. This suggests it would be unwise for the company to pay the CEO too generously.

Ross Murdoch is paid around what is normal the leaders of comparable size companies.

We think that the EPS growth is very pleasing, but we find the returns over the last three years to be lacking. We'd be surprised if shareholders want to see a pay rise for the CEO, but we'd stop short of calling their pay too generous. CEO compensation is one thing, but it is also interesting to check if the CEO is buying or selling Avecho Biotechnology (free visualization of insider trades).

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Read more here:
Should You Be Pleased About The CEO Pay At Avecho Biotechnology Limited's (ASX:AVE) - Yahoo Finance

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at http://www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

As with many websites, JD Supra's website (located at http://www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

We use cookies and other tracking technologies to:

There are different types of cookies and other technologies used our Website, notably:

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

Read more here:
New Joint Website on Agricultural Biotechnology Products Launched by EPA, USDA, and FDA - JD Supra

MIRAMAR, Fla., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that their subsidiary, Olaregen Therapeutix, Inc., is introducing an exciting new product, Excellagen Aesthetics for the cosmetic surgery and aesthetic dermatology market. FDA 510(k) cleared with an indication for the management of wounds, Excellagen Aesthetics is intended for use following facial rejuvenation procedures, including post-laser surgery, post-chemical peels, and post- skin ablation. Excellagen is a ready to use 3-dimensional wound conforming matrix that supports a favorable wound healing environment. It is designed to activate collagen, accelerate granulation, and promote new tissue growth by providing a structural scaffold for cellular migration and proliferation. Excellagen Aesthetics has been shown in vitro to trigger the localized release of endogenous growth factors including Platelet-Derived Growth Factor (PDGF), a key biological mediator of wound healing.

Olaregen is rolling out Excellagen Aesthetics with a dedicated contract sales force uniquely positioned in major metropolitan areas across the United States where the majority of aesthetic dermatology procedures are clustered. Americans spent an estimated $8 billion on surgical and non-surgical aesthetic dermatology procedures in 2018 when there were over 340,000 facial rejuvenation performed.

Scott Emmens, Senior Vice President of Sales and Business Development at Olaregen commented, We have been working closely with the aesthetic dermatology community, and Excellagen Aesthetics is being tested with some leading dermatologists who are conducting case studies to evaluate the efficacy of our cellular tissue product in wound management as measured by patient reported down-time as well as patient satisfaction with post-treatment care. We are enthusiastic about the early response from patients and doctors who have tried the product after facial rejuvenation procedures including micro-needling and laser skin resurfacing, two procedures that result in post-treatment pain and significant healing times that limit daily activities. We look forward to engaging with the dermatology community to introduce Excellagen Aesthetics and show how our FDA-cleared product can be used to the benefit of their patients and their practice.

About Generex Biotechnology Corp.

Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital.

About Olaregen Therapeutix

Olaregen Therapeutix, Inc. is a regenerative medicine company focused on the development, manufacturing and commercialization of products that fill unmet needs in the current wound care market. The company aims to provide advanced healing solutions that substantially improve medical outcomes while lowering the overall cost of care. Olaregen's first product introduction, Excellagen (flowable dermal matrix) is a topically applied product for dermal wounds and other indications. Excellagen is a FDA 510K cleared device for a broad array of dermal wounds, including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/ grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds, enabling Olaregen to market Excellagen in multiple vertical markets. in bone and joint regeneration comprise the current pipeline. The company's mission is to become a significant force in regenerative medicine and advance the science of healing.

Story continues

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato 646-599-6222

Todd Falls 1-800-391-6755 Extension 222 investor@generex.com

Excerpt from:
Generex Biotechnology Subsidiary Olaregen Therapeutix Announces the Introduction of Excellagen Aesthetics - Yahoo Finance

Low cost of capital has fueled exceptional returns for biotech and health stocks but will near zero cost financing last?

Biotechnology & Healthcare was the top performing investment company sector of the last decade producing a return of 491% from 2010 to 2019, compared to a return of 198% for the average investment company over the same period, according to the Association of Investment Trusts (AIC).

The UK Smaller Companies and Global Smaller Companies sectors were the second and third best performing sectors of the decade and delivered 379% and 330% respectively. European Smaller Companies (10th) also featured in the top ten.

Meanwhile the best performing investment companies over the past decade came from a variety of sectors, but companies in the UK Smaller Companies sector featured most strongly, making four appearances within the top ten.

Volta Finance was the best performing member company over the decade. The company from the Debt Structured Finance sector produced an impressive 959% share price total return from 1 January 2010 to 31 December 2019. It was followed by Lindsell Train in the Global sector, up 730%, and Baillie Gifford Shin Nippon from the Japanese Smaller Companies sector, up 678% over the same period.

Annabel Brodie-Smith, communications director of the AIC said: Its encouraging to see a diverse spectrum of investment company sectors perform so strongly over the last decade. While Biotechnology & Healthcare was the top performing sector by some margin, two UK equity sectors made it into the top ten despite the Brexit referendum and subsequent lack of clarity surrounding the UKs exit.

The closed-ended investment company structure lends itself particularly well to illiquid alternative investments and over the past decade the Private Equity and Infrastructure sectors have both delivered particularly strong returns. Three smaller company sectors feature in the top ten best performers, demonstrating that investment companies are the best vehicle for holding smaller companies which can be hard to sell in times of stress. In addition, investors who have favoured investment companies to gain overseas exposure via the Japan, Global and North America sectors have been handsomely rewarded.

Its always interesting to look back at the best performing companies, but its important to remember that past performance is not an indicator of future returns. Investment companies cover a broad variety of sectors, risk profiles and geographical exposure to match a range of investor needs. When investing you should consider your objectives and the level of risk you are willing to take and, if you have any concerns, you should speak to a financial adviser.

Jason Hollands, managing director, business development and communications at Tilney Investment Management Services said: The last decade has seen huge advances in medical discovery. When combined with an extraordinarily supportive, post global crisis environment for risk assets i.e. low cost of capital thats fueled exceptional returns for biotech and health stocks.

While there is no reason to doubt further advancements in medical science, we wont remain locked in a world of near zero real financing costs forever. Of particular relevance is mounting pressure across the global for greater controls over drug pricing, given the spiraling costs to health services. This could be particularly relevant if the Democrats win the US Presidential election as their nominees have been vocal on this as well as calling for a much more interventionist role for the state in the massive US healthcare market.

With regards to the overall observations below. The broad theme is that smaller companies across a variety of markets have been amongst the best performing parts of the market. Ironically this has taken place over a period during which investors have increasingly shunned them in the clamour for passive products that are overwhelming skewed to large-cap companies. Frankly, the more smaller companies are ignored, the greater the potential available for active managers to add value in this space by spotting winners that the wider market has yet to discover.

Further reading: Investment Trusts: A beginners guide

Visit link:
Biotechnology and Healthcare is the best performing IT fund sector - What Investment

The GlobalWorkforce Management Applications Software Market2019 report implement in-depth research of the industry with a focus on the current market trends future prospects. The GlobalWorkforce Management Applications Software Marketreport aims to provide an overview ofWorkforce Management Applications Software Marketplayers with detailed market segmentation by product, application and geographical region. It also provides market share and size, revenue forecast, growth opportunity. The most recent trending report WorldwideWorkforce Management Applications Software MarketEconomy by Manufacturers, Regions, kind and application, forecast to 2024 provided byReports and Reportsis an educational study covering the marketplace with detailed analysis.

The report projects the market size by the end of 2024 at an exponential CAGR, by analyzing the historical data for the time period of 2018. The prime objective of this report is to determine Global Workforce Management Applications Software Market status, forecast, growth opportunity, and market size by studying classification such as key players, regional segments type and application.

GetFree Sample Copy of Workforce Management Applications Software Market:https://www.reportsnreports.com/contacts/requestsample.aspx?name=2626507

The important regions, considered to prepare this report are North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa). The region wise data analyses the trend, market size of each regions Workforce Management Applications Software Market. It also helps to determine the market share, growth prospects and challenges at the regional level. As per the report, the Asia-Pacific will vouch for more market share in following years, emphasizing more in China. India and Southeast Asia regions will also record considerable growth. North America, especially The United States, will still play a significant role up to an extent that changes in United States market might affect the development trend of Workforce Management Applications Software Market Industry. Europe will hold a vital contribution too with impressive CAGR till 2024.

Other than the aforementioned parameters which Workforce Management Applications Software Market report focuses on, another imperative objective of the report is to present the Workforce Management Applications Software Market development across the globe especially in North America, Europe, China, Japan, Southeast Asia, India and Central and South America. In the report, the market has been categorized into manufacturers, type, application and regions.

Scope of the Report:The global Workforce Management Applications Software market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Workforce Management Applications Software.Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.This report studies the Workforce Management Applications Software market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Workforce Management Applications Software market by product type and applications/end industries.

Market Segment by Companies, this report covers Teleopti Genesys Aspect Verint Systems Calabrio ZOOM International OpenText NICE Injixo Avaya (Verint) Envision DVSAnalytics Five9 Altitude CSI 88 VoiceCyber West Verint Monet

Market Segment by Regions, regional analysis coversNorth America (United States, Canada and Mexico)Europe (Germany, France, UK, Russia and Italy)Asia-Pacific (China, Japan, Korea, India and Southeast Asia)South America (Brazil, Argentina, Colombia)Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers Cloud-Based On-Premises

Market Segment by Applications, can be divided into Large Enterprises(1000+ Users) Medium-Sized Enterprise(499-1000 Users) Small Enterprises(1-499 Users)

Enquire on Workforce Management Applications Software Market:https://www.reportsnreports.com/contacts/discount.aspx?name=2626507

This report studies the Workforce Management Applications Software Marketstatus and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Workforce Management Applications Software Marketby product type and applications/end industries. These details further contain a basic summary of the company, merchant profile, and the product range of the company in question. The report analyzes data regarding the proceeds accrued, product sales, gross margins, price patterns, and news updates relating to the company.

Thus, this report can be a guideline for the industry stakeholders, who wished to analyze the Workforce Management Applications Software Market and understand its forecast of till 2024. This report helps to know the estimated market size, market status, future prospects, growth opportunity, and main challenges of Workforce Management Applications Software Market by analyzing the segmentations.

About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.

We provide 24/7 online and offline support to our customers.

E-mail: [emailprotected]

Phone: +1 888 391 5441

Qurate Business Intelligence delivers unique market research solutions to its customers and help them to get equipped with refined information and market insights derived from reports. We are committed to providing best business services and easy processes to get the same. Qurate Business Intelligence considers themselves as strategic partners of their customers and always shows the keen level of interest to deliver quality.

Follow this link:
Food Biotechnology: Market 2020 Strong Development By Major Eminent Players, New Innovations, Key Business Strategies, Trend and Forecasts 2024 -...

Adaptimmune Therapeutics plc and Japanese Astellas Pharma, Inc. have signed a discovery partnership to develop off-the-shelf allogeneic T cell-based cancer therapies from stem cells.

At J.P. Morgan conference, the British company announced that Astellas has agreed to co-develop and co-commercialize stem-cell derived allogeneic CAR-T and TCR T-cell therapies against up to three targets. In contrast to current autologous T cell therapies, allogenic T cell therapies might be manufactured in a central facility reducing production cost significantly compared to autologous cell production and logistics.

Under the agreement, Adaptimmune will identify and validate new targets for generating target-specific T-cell receptors (TCRs), chimeric antigen receptors (CARs), and HLA-independent TCRs that recognize surface epitopes independently from the HLA profile of the tumour cell. Astellas subsidiary Universal Cells, Inc will provide its Universal Donor Cell and Gene Editing Platform, which makes use of a stem cell-tropic rAAV vector for engineering humanpluripotent stem cells to contain deletions, insertions, or point mutations at any genomic position.

Adaptimmune has been collaborating with Universal Cells since 2015 on development of gene-edited induced pluripotent stem cell (iPSC) lines that generate proprietary T-cell products without the use of feeder layers.

Under the agreement, Astellas will fund research up until completion of a Phase I trial for each candidate with US$7.5m per year. Subsequently, Astellas and Adaptimmune may opt for co-development and co-commercialization of the candidate, or independent development through a milestone and royalty bearing licence. Under the agreement, Astellas will also have the right to select two targets and develop allogeneic cell therapy candidates on its own.

In case of Astellas would develop the candidates on its own, Adaptimmune may receive up to$897.5m in payments. If Adaptimmune would do so, Astellas may receive up to US$552.5m. If the companies opt for co-commercialisation any T-cell therapy, costs and profits will be shared equally.

More:
Astellas and Adaptimmune team up in CAR-T development - European Biotechnology

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.

Given this risk, we thought wed take a look at whether Vir Biotechnology (NASDAQ:VIR) shareholders should be worried about its cash burn. In this report, we will consider the companys annual negative free cash flow, henceforth referring to it as the cash burn. Well start by comparing its cash burn with its cash reserves in order to calculate its cash runway.

See our latest analysis for Vir Biotechnology

A companys cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. As at September 2019, Vir Biotechnology had cash of US$320m and no debt. Importantly, its cash burn was US$130m over the trailing twelve months. That means it had a cash runway of about 2.5 years as of September 2019. Thats decent, giving the company a couple years to develop its business. You can see how its cash balance has changed over time in the image below.

Some investors might find it troubling that Vir Biotechnology is actually increasing its cash burn, which is up 39% in the last year. And we must say we find it concerning that operating revenue dropped 4.0% over the same period. Taken together, we think these growth metrics are a little worrying. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

Even though it seems like Vir Biotechnology is developing its business nicely, we still like to consider how easily it could raise more money to accelerate growth. Companies can raise capital through either debt or equity. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash to fund growth. By comparing a companys annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).

Since it has a market capitalisation of US$1.6b, Vir Biotechnologys US$130m in cash burn equates to about 8.2% of its market value. Given that is a rather small percentage, it would probably be really easy for the company to fund another years growth by issuing some new shares to investors, or even by taking out a loan.

Even though its increasing cash burn makes us a little nervous, we are compelled to mention that we thought Vir Biotechnologys cash runway was relatively promising. Cash burning companies are always on the riskier side of things, but after considering all of the factors discussed in this short piece, were not too worried about its rate of cash burn. While we always like to monitor cash burn for early stage companies, qualitative factors such as the CEO pay can also shed light on the situation. Click here to see free what the Vir Biotechnology CEO is paid..

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies insiders are buying, and this list of stocks growth stocks (according to analyst forecasts)

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

See the rest here:
Companies Like Vir Biotechnology (NASDAQ:VIR) Are In A Position To Invest In Growth - Simply Wall St

Despite the fact that Donald Trump's government is determined to continue sanctioning Cuba - the charter flights from the U.S. to nine Cuban airports were suspended last week because of the country's support for Maduro's regime, according to statements by Secretary of State Mike Pompeo - the collaboration between the United States and the island continues, at least on scientific matters. And this should not surprise us, taking into account the great medical advances made by Cuban professionals in the treatment of various types of cancer.

This is what we'll be able to witness in "Cuba's Cancer Hope," a documentary by Llew Smith that will be released next April by PBS and that sheds light on CimaVax, a revolutionary treatment against lung cancer that prolongs the life of patients in very advanced stages and that the Center of Molecular Immunology (CIM) in Habana has taken more than twenty years to develop.

In fact, the results are so encouraging that the Roswell Park Comprehensive Cancer Center in New York soon joined the project and will be the first U.S. institution to conduct a clinical trial of the drug produced on the island.

"The future of our country must necessarily be a future of men of science and thought, because that is precisely what we are sowing most," Fidel Castro, 1960.

Llew Smith himself was one of the volunteers to test this pioneering treatment, according to Prensa Latina, and his results, which were made known two years ago, will be part of the documentary.

"The wonderful thing about working with our Cuban colleagues is that they really believe, in their heart of hearts, that medical care is a human right," said Dr. Kevin Lee, director of the Roswell Park immunology department, in a dialogue with the press, praising the medical advances being made in Cuba and its "great potential to treat and prevent cancer of various kinds."

Cuba a pioneer in science

Biotechnology is one of the most developed branches of Cuban science, which began to be promoted in 1980, when Fidel Castro's government created a group dedicated to the production of interphenon, a possible cancer drug, in addition to promoting scientific parks.

This is a commitment to progress that the current president of Cuba, Miguel Daz-Canel Bermdez, acknowledged to Castro on the occasion of the documentary, and which the late revolutionary leader already advocated in a speech made in 1960when he said:

"The future of our country must necessarily be a future of men of science and thoughtbecause that is precisely what we are sowing most."

But the CimaVax is not the only discovery of Cuban scientists, whose achievements can be traced in the history of the island:

In 1881, the scientist Carlos Juan Finlay was the discoverer of the agent that transmits yellow fever, the Aedes aegypti mosquito, which made it possible to clean up the areas invaded by this infectious agent and which, in the end, has prevented millions of deaths.

"The wonderful thing about working with our Cuban colleagues is that they truly believe, deep in their hearts, that medical care is a human right," Dr. Kevin Lee from Roswell Park.

Also at Cuba's Center for Genetic Engineering and Biotechnology (CIGB), Heberprot-P was developed, a unique drug that prevents the amputation of diabetic feet by healing ulcers.

In addition, Cuba was recognized by WHO as the first country in the world to eliminate mother-to-child transmission of HIV.

The documentary "Cuba's Cancer Hope" also includes other therapies being experimented with on the island, specifically for the treatment of different types of cancer, which once again confirms that health does not understand colors and scientific advances are breaking down the walls that apparently separate us.

Go here to see the original:
Cuba's revolutionary cancer vaccine builds bridges between the island and the United States - AL DIA News

Even when a business is losing money, its possible for shareholders to make money if they buy a good business at the right price. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, youd have done very well indeed. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.

So should Unity Biotechnology (NASDAQ:UBX) shareholders be worried about its cash burn? For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. Well start by comparing its cash burn with its cash reserves in order to calculate its cash runway.

See our latest analysis for Unity Biotechnology

A companys cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. Unity Biotechnology has such a small amount of debt that well set it aside, and focus on the US$113m in cash it held at September 2019. Importantly, its cash burn was US$71m over the trailing twelve months. That means it had a cash runway of around 19 months as of September 2019. While that cash runway isnt too concerning, sensible holders would be peering into the distance, and considering what happens if the company runs out of cash. The image below shows how its cash balance has been changing over the last few years.

Some investors might find it troubling that Unity Biotechnology is actually increasing its cash burn, which is up 25% in the last year. In light of that, the flat year on year operating leverage is a bit off-putting. In light of the data above, were fairly sanguine about the business growth trajectory. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

Unity Biotechnology seems to be in a fairly good position, in terms of cash burn, but we still think its worthwhile considering how easily it could raise more money if it wanted to. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash to fund growth. We can compare a companys cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one years operations.

Unity Biotechnologys cash burn of US$71m is about 21% of its US$334m market capitalisation. Thats not insignificant, and if the company had to sell enough shares to fund another years growth at the current share price, youd likely witness fairly costly dilution.

Even though its increasing cash burn makes us a little nervous, we are compelled to mention that we thought Unity Biotechnologys cash runway was relatively promising. Even though we dont think it has a problem with its cash burn, the analysis weve done in this article does suggest that shareholders should give some careful thought to the potential cost of raising more money in the future. For us, its always important to consider risks around cash burn rates. But investors should look at a whole range of factors when researching a new stock. For example, it could be interesting to see how much the Unity Biotechnology CEO receives in total remuneration.

Of course Unity Biotechnology may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

View post:
We Think Unity Biotechnology (NASDAQ:UBX) Needs To Drive Business Growth Carefully - Simply Wall St